187 related articles for article (PubMed ID: 2500599)
1. Serpin-resistant mutants of human tissue-type plasminogen activator.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
[TBL] [Abstract][Full Text] [Related]
2. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
3. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
Rezaie AR
Biochemistry; 1998 Sep; 37(38):13138-42. PubMed ID: 9748320
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of human tissue-type plasminogen activator (t-PA).
van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
[TBL] [Abstract][Full Text] [Related]
7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
8. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
Masson C; Angles-Cano E
Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
10. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
11. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
[TBL] [Abstract][Full Text] [Related]
12. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
15. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.
Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W
J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982
[TBL] [Abstract][Full Text] [Related]
16. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF; Bassel-Duby RS
Proc Natl Acad Sci U S A; 1990 May; 87(9):3530-3. PubMed ID: 2110366
[TBL] [Abstract][Full Text] [Related]
17. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
Michel JB; Quertermous T
J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
[TBL] [Abstract][Full Text] [Related]
18. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
19. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
20. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
